K-ras gene point mutations and p21ras immunostaining in human ovarian tumors

European Journal of Gynaecological Oncology

Volumn 25, Issue 4, 2004, Pages 484-488

  Semczuk, A ^a   Postawski, K ^a   Przadka, D ^a   Rozynska, K ^a   Wrobel, A ^a   Korobowicz, E ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

K ras; Ovarian cancer; PCR; RFLP

Indexed keywords

PROTEIN P21;

ADULT; ARTICLE; CARCINOGENESIS; CODON; CONTROLLED STUDY; CYSTADENOMA; DYSGERMINOMA; EXCISION REPAIR; FEMALE; FOLLICULOMA; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MISMATCH REPAIR; ONCOGENE K RAS; OVARY ADENOCARCINOMA; OVARY METASTASIS; OVARY TUMOR; POINT MUTATION; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; BIOPSY, NEEDLE; CODON; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEIN P21(RAS); OVARIAN NEOPLASMS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROBABILITY; PROGNOSIS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 3242718872     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Matias-Guiu X., Prat J.: "Molecular pathology of ovarian carcinomas". Virchows Arch., 1998, 433, 103.
2. Aunoble B., Sanches R., Didier E., Bignon Y.J.: "Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer". Int. J. Oncol., 2000, 16, 567.
3. nd ed., San Diego, Academic Press, 1997, 319.
4. Spandidos D.A., Sourvinos G., Tsatsanis C., Zafiropoulos A.: "Normal ras genes: Their onco-suppressor and pro-apoptotic functions". Int. J. Oncol., 2002, 21, 237.
5. Waldmann V., Rabes H.M.: "What's new in ras genes? Physiological role of ras genes in signal transduction and significance of ras gene activation in tumorigenesis". Pathol. Res. Pract., 1996, 192, 883.
6. Pruitt K., Der C.J.: "Ras and Rho regulation of the cell cycle and oncogenesis". Cancer Lett., 2001, 171, 1.
7. Kiaris H., Spandidos D.A.: "Mutations of ras genes in human tumours". Int. J. Oncol., 1995, 7, 413.
8. Wang J.Y., Chen F.M., Hsieh J.S., Huang T.J., Lin S.R.: "High frequency of K-ras codon 15 mutations in colorectal carcinomas from Taiwanese patients". Int. J. Mol. Med., 2002, 10 (suppl.), S47.
9. Varras M.N., Sourvinos G., Diakomanolis E., Koumantakis E., Flouris G.A., Lekka-Katsouli J. et al.: "Detection and clinical correlations of ras gene mutations in human ovarian tumors". Oncology, 1999, 56, 89.
10. Enomoto T., Weghorts C.M., Inoue M., Tanizawa O., Rice J.: "K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary". Am. J. Pathol., 1991, 139, 777.
11. Fujita M., Enomoto T., Inoue M., Tanizawa O., Ozaki M., Rice J.M. et al.: "Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary". Jpn. J. Cancer Res., 1994, 85, 1247.
12. Ichikawa Y., Nishida M., Suzuki H., Yoshida S., Tsunoda H., Kubo T. et al.: "Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors". Cancer Res., 1994, 54, 33.
13. Cautrecasas M., Villanueva A., Matias-Guiu X., Prat J.: "K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases". Cancer, 1997, 79, 1581.
14. Morita K., Ono Y., Fukui H., Tomita S., Ueda Y., Terano A. et al.: "Incidence of p53 and K-ras alterations in ovarian mucinous and serous tumors". Pathol. Int., 2000, 50, 219.
15. Garrett A.P., Lee K.R., Colitti C.R., Muto M.G., Berkowitz R.S., Mok S.C.: "K-ras mutation may be an early event in mucinous ovarian tumorigenesis". Int. J. Gynecol. Pathol., 2001, 20, 224.
16. Mok S.C.-H., Bell D.A., Knapp R.C., Fishbaugh P.M., Welch W.R., Muto M.G. et al.: "Mutation of K-ras protooncogene in human epithelial tumors of borderline malignancy". Cancer Res., 1993, 53, 1489.
17. Teneriello M.G., Elbina M., Linnoila R.I., Henry M., Nash J.D., Park R.C. et al.: "p53 and Ki-ras gene mutations in epithelial ovarian neoplasms". Cancer Res., 1993, 53, 3103.
18. Mandai M., Konishi I., Kuroda H., Komatsu T., Yamamoto S., Nanbu K. et al.: "Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology". Hum. Pathol., 1998, 28, 34.
19. nd ed., Springer, Berlin, 1994.
20. Semczuk A., Berbec H., Kostuch M., Cybulski M., Wojcierowski J., Baranowski W.: "K-ras gene point mutations in human endometrial carcinomas: Correlation with clinicopathological features and patients' outcome". J. Cancer Res. Clin. Oncol., 1998, 124, 695.
21. Stenzel A., Semczuk A., Rozynska K., Jakowicki J., Wojcierowski J.: "Low-risk' and 'high-risk' HPV-infection and K-ras gene point mutations in human cervical cancer: A study of 31 cases". Pathol. Res. Pract., 2001, 197, 597.
22. Semczuk A., Miturski R., Baranowski W., Jakowicki J.A.: "ras p21 immunohistochemical detection in human endometrial carcinomas". Gynecol. Obstet. Invest., 1997, 44, 132.
23. Miturski R., Semczuk A., Jakowicki J.A.: "Expression of ras p21 in the stromal cells of human neoplastic endometrium". Eur. J. Gynaecol. Oncol., 1998, 19, 308.
24. Semczuk A., Berbec H., Kostuch M., Kotarski J., Wojcierowski J.: "Detection of K-ras mutations in cancerous lesions of human endometrium". Eur. J. Gynaecol. Oncol., 1997, 18, 80.
25. Semczuk A., Schneider-Stock R., Berbeć H., Marzec B., Jakowicki J.A., Roessner A.: "K-ras exon 2 gene point mutations in endometrial cancer". Cancer Lett., 2001, 164, 207.
26. Fujita M., Enomoto T., Murata Y.: "Genetic alterations in ovarian carcinoma with specific reference to histological subtypes". Mol. Cell Endocrinol., 2003, 202, 97.
27. Suzuki M., Saito S., Saga Y., Ohwada M., Sato I.: "Mutation of K-ras protooncogene and loss of heterozygosity on 6q27 in serous and mucinous ovarian carcinomas". Cancer Genet. Cytogenet., 2000, 118, 132.
28. Haas C.J., Diebold J., Hirschmann A., Rohrbach H., Lohrs U.: "In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential". Virchows Arch., 1999, 434, 117.
29. Singer G., Kurman R.J., Chang H.W., Cho S.K., Shih I.M.: "Diverse tumorigenic pathways in ovarian serous carcinoma". Am. J. Pathol., 2002, 160, 1223.
30. Singer G., Shih I.M., Truskinovsky A., Umudum H., Kurman R.J.: "Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (Low-grade tumor) and conventional serous carcinoma (High-grade tumor)". Int. J. Gynecol. Pathol., 2003, 22, 37.
31. Ortiz B.H., Ailawadi M., Colitti C., Muto M.G., Deavers M., Silva E.G. et al.: "Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors". Cancer Res., 2001, 61, 7264.
32. Gemignani M.L., Schlaerth A.C., Bogomolniy F., Barakat R.R., Lin O., Soslow R. et al.: "Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma". Gynecol. Oncol., 2003, 90, 378.
33. Gulbis B., Galand P.: "Immunodetection of the p21-ras products in human normal and preneoplastic tissues and solid tumors: A review". Hum. Pathol., 1993, 24, 1271.
34. Yaginuma Y., Yamashita K., Kuzumaki N., Fujita M., Shimizu T.: "ras oncogene product p21 expression and prognosis of human ovarian tumors". Gynecol. Oncol., 1992, 46, 45.
35. Scambia G., Masciullo V., Benedetti-Panici P., Marone M., Ferrandina G., Todaro N. et al.: "Prognostic significance of ras/p21 alterations in human ovarian cancer". Br. J. Cancer, 1997, 75, 1547.
36. Konishi N., Enomoto T., Buzard G., Ohshima M., Ward J.M., Rice J.M.: "K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men". Cancer, 1992, 69, 2293.
37. Tsuda T., Mochizuki M., Wakasa H.: "Detection of c-ras gene mutation and expression of p21 protein in dysplasias and carcinomas complicating ulcerative colitis". J. Gastroenterol., 1995, 30 (suppl. 8), 30.
38. Kasper H.-U., Schneider-Stock R., Mellin W., Roessner A.: "p21 protein expression and ras-oncogene mutations in gastric carcinoma: Correlation with clinical data". Int. J. Oncol., 1998, 12, 69.